TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US

 

 

 

 

 

Home Page  |  

 

April 12, 2005
PRESS RELEASE:

PEGASUS/HEARTVIEW CLINICAL TRIAL FOR HEART DISEASE SCREENING DEVICE UNDERWAY IN NEW YORK .

(Please note that the name of the Cardiovisor 6S System has since been changed to HeartVue™ 6S System)  

Palm Beach Gardens , Fla. - Business Wire - April 12, 2005 . Pegasus Pharmaceuticals Inc. (OTC-PGUZ) has acquired 51% of Heartview LLC, a Cleveland, Ohio-based corporation.  

Heartview has developed a portable heart screening device which provides physicians with a faster, more accurate method for earlier detection of heart diseases. The Cardiovisor 6S System conducts an ECG data analysis and builds and displays a color-coded topological portrait of heart electrical activity providing principally new information about the heart state after only 60 seconds. This faster, more portable device has tremendous potential in cutting costs associated with ischemic heart disease and for screening populations.  

The Cardiovisor 6S heart screening system is currently undergoing clinical trials at a major hospital in New York , N.Y.  

On behalf of the Board of Directors,

Dan Kesonen, Chairman & CEO,
Pegasus Pharmaceuticals Inc.

For more information, please contact Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc. at (561) 626-9901.

 


 


Copyright © 2006, Pegasus Pharmaceuticals Inc.